ANGO News and Press, AngioDynamics Inc. From 03/15/25

2025-03-15 11:00:00 ET Get ahead of the market by subscribing to Seeking Alpha's Wall Street Week Ahead, a preview of key events scheduled for the coming week. The newsletter keeps you informed of the biggest stories set to make headlines, including upcoming IPOs, investor days, earnings ...

2025-03-14 15:00:10 ET More on the markets SPY: A Rebound Is Coming (Rating Upgrade) Yes, Bear Market Risk Has Skyrocketed Dramatically 5 Bursting Bubbles BofA sets the S&P buy level S&P correction: Biggest decliners as index logs first 10% fa...

2025-03-12 21:00:04 ET Summary Penumbra's shares have surged again on renewed confidence in mechanical thrombectomy growth and a competitor's acquisition, but the current valuation is high at over 7x 2025 revenue estimate. Penumbra's thrombectomy business grew significantly in Q4'...

AngioDynamics, Inc. (NASDAQ: ANGO), a leading and transformative medical technology company focused on restoring healthy blood flow in the body’s vascular system, expanding cancer treatment options, and improving quality of life for patients, today announced that Jim Clemmer, President and...

Trial Evaluates Effectiveness of Innovative Auryon Atherectomy System in Complex Below-the-Knee Cases AngioDynamics, Inc. (NASDAQ: ANGO), a leading and transformative medical technology company focused on restoring healthy blood flow in the body's vascular system, expanding cancer treat...

2025-01-16 05:07:22 ET Summary AngioDynamics' fiscal Q2'25 results exceeded expectations, with Med Tech growing 25% and delivering better gross margins, boosting confidence in achieving high single-digit revenue growth and double-digit EBITDA margins in time. Clinical data for Alp...

2025-01-15 08:10:00 ET The growing prevalence of chronic diseases like cancer and diabetes is driving increasing innovation in medical device technology. In 2024 alone, 30 new devices were approved by the US Food and Drug Administration (FDA). Wearable medical devices and th...

Peer-reviewed data highlights successful clinical study with 35.5% clot burden reduction, validating the safety, efficacy, and efficiency of AlphaVac F18 85 System in pulmonary embolism treatment. AngioDynamics, Inc. (NASDAQ: ANGO), a leading and transformative medical technology ...

2025-01-08 17:15:55 ET Summary AngioDynamics, Inc.'s Q2 2025 earnings beat expectations, with non-GAAP EPS at -$0.04 and revenue at $73.02 million, driving a 35% stock surge. Med Tech division shines, with 25% revenue growth and key products like Auryon, AlphaVac, and AngioVac sho...

2025-01-08 11:00:42 ET AngioDynamics, Inc. (ANGO) Q2 2025 Earnings Conference Call January 08, 2025, 8:00 AM ET Company Participants Jim Clemmer - President and Chief Executive Officer Stephen Trowbridge - Executive Vice President and Chief Financial Officer Co...